Business Context and Reporting Period
This Form 8-K Current Report was filed by Trxade Group, Inc. (noted as Scientificure Holdings, Inc. in metadata) on November 20, 2019. The registrant is an emerging growth company incorporated in Delaware. The filing primarily addresses corporate governance changes, specifically the resignation and appointment of Board of Directors members, and the formation of a new committee to support a planned uplisting to the Nasdaq Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial statements or performance metrics.
Material Changes
- Resignation of Director: Gary Augusta resigned from the Board of Directors effective November 20, 2019. The resignation was mutual and not due to any disagreement regarding operations or policies. Mr. Augusta stepped down because his active participation in the company's planned Nasdaq uplisting process likely disqualified him from meeting the definition of an "independent director" under Nasdaq rules.
- Appointment of Director: Dr. Pamela Tenaerts was appointed to the Board of Directors effective November 20, 2019, to fill the vacancy. The Board determined she is "independent" under Nasdaq Capital Market rules. She was also appointed to the Audit Committee.
- Committee Formation: The Board formed a Nominating and Corporate Governance Committee and adopted its charter. Mr. Donald G. Fell was appointed Chairman, and Mr. Michael L. Peterson was appointed as a member.
Guidance, Outlook, and Risks
Outlook: Management indicated that the company is actively pursuing a planned uplisting to the Nasdaq Capital Market. The governance changes were made to ensure compliance with Nasdaq independence requirements for this process.
Risks and Contingencies: The filing notes no disagreements between the departing director and the company. There are no material plans, contracts, or related party transactions involving the newly appointed director, Dr. Tenaerts.
Key Facts for Investor Verification
- Verify the company's current progress toward the planned Nasdaq Capital Market uplisting.
- Confirm the independence status of the new Board members (Dr. Tenaerts, Mr. Fell, Mr. Peterson) in subsequent filings.
- Review the full Charter of the Nominating and Corporate Governance Committee (Exhibit 99.1) for governance standards.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial performance.